Recordati Industria Chimica e Farmaceutica SPA (IT:REC) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Recordati has successfully acquired global rights to Enjaymo®, a groundbreaking treatment for cold agglutinin disease, from Sanofi. The acquisition is expected to boost revenue significantly, with Enjaymo® projected to generate over 150 million euros in 2025. This strategic addition strengthens Recordati’s rare diseases portfolio and promises strong financial returns.
For further insights into IT:REC stock, check out TipRanks’ Stock Analysis page.
